A simple lotion duo may shield skin from Tumor-Treating fields

NCT ID NCT04469075

Ongoing Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether applying two topical lotions, clindamycin and triamcinolone, can prevent skin irritation caused by Tumor Treating Fields (TTFields) in people with glioblastoma. Participants will use the lotions at each array change, and researchers will track how many develop significant skin toxicity and how it affects their quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clindamycin and triamcinolone topical lotions
What this could lead to: If effective, this could offer a simple way to prevent skin irritation from TTFields, improving comfort and quality of life for glioblastoma patients.
What could go wrong: This is a small phase II trial, so results may not be conclusive. The lotions may not prevent all skin reactions, and some patients may experience allergies or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA RECURRENT GLIOBLASTOMA SKIN TOXICITY

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Hackensack Meridian Health

Hackensack, New Jersey, 07601, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities)

Hauppauge, New York, 11788, United States
Northwestern University

Evanston, Illinois, 60208, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.